Tema Oncology ETF CANC
Set alert
41.67 USD -0.56 -1.32%
At close · Nov 2
41.69 +0.02 +0.04%
After hours · Nov 2, 4:00 PM ET
41.67 Day range 42.32
30.14 52-week range 47.00
- YTD
- +20.02%
- 1 year
- +34.51%
- Open
- 42.07
- Prev close
- 42.23
- Mkt cap
- 134.16M
- Vol
- 13.80K
- Avg vol
- 24.14K
- EPS
- 1.59
- P/E
- 26.21
- Div yield
- 0.00%
More statistics
- Low
- 41.67
- High
- 42.32
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 27.30
- 200-d avg
- 27.72
2Y chart
Events in this range
- Dec 11, 2024Dividend: 0.72827
- Dec 10, 2025Dividend: 0.0195905
Signals (86)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 2026 | 16 hours ago |
| SMA: Bullish | Oct 28, 2026 | 5 days ago |
| MACD: Buy Signal | Oct 20, 2026 | 1 week ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| SMA: Bullish | Sep 22, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| RSI: Overbought | Aug 19, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 7, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 14, 2026 | 3 months ago |
| RSI: Overbought | Jul 9, 2026 | 3 months ago |
| RSI: Overbought | Jul 2, 2026 | 4 months ago |
| RSI: Overbought | Jun 26, 2026 | 4 months ago |
| SMA: Bullish | Jun 22, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 15, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 2, 2026 | 5 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| MACD: Buy Signal | May 22, 2026 | 5 months ago |
| SMA: Bullish | May 20, 2026 | 5 months ago |
| SMA: Bearish | May 15, 2026 | 5 months ago |
Newest 20 of 86.
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 27.30
- 200-day average
- 27.72
About Tema Oncology ETF
Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.
News
- EXCLUSIVE: AI, Genomics Could Fuel Biotech ETF Re-Rating as Health Care Trades at Discount, Says Expert
- Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough
- Biotech ETF (CANC) Hits New 52-Week High
- Tema ETFs Exceeds $5bn in AUM After Three Years
- Tema ETFs Surpasses $2 Billion in AUM in Under Three Years
- CANC: I Give A Hold Rating To This ETF That Invests In Cancer-Fighting Stocks
- Cogent Biosciences Stock Climbs After FDA Accepts Key Drug Application
- Tema Appoints ETF Industry Leader Steve Munroe as President
- Thrivent Financial for Lutherans Decreases Stake in Tema Oncology ETF $CANC
- Tema's Oncology ETF (CANC) Surpasses $100m in Assets Amidst Strong 2025 Performance
Your note
Sign in to keep a note on CANC — it syncs with the Stock Master app.